Physiological pharmacokinetics model, significance

Johanson. G. Filser, J.G. (1993) A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation. Arch. Toxicol., 61, 151-163... 

A physiologically based pharmacokinetic model for predicting ethylene dibromide kinetics and consequent toxicity, based on in-vitro metabolic parameters of rodents and humans and on the use of scaling factors, has been presented (Ploemen et al., 1997). Its most important prediction is that the GST pathway is significantly active even at low ethylene dibromide concentrations, which has important implications for risk assessment. 

Tardif et al. (1997) developed a physiologically based pharmacokinetic model for zneio-xylene in rats and humans. They also simulated interactions between weto-xylene, toluene and ethylbenzene, and showed that for exposures at air concentrations remaining within the permissible range for a mixture, biologically significant interactions at the pharmacokinetic level would not occur. 

---